Abstract: The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic ?7 receptor agonist, a ?3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

Abstract: A method for machine learning based artifact rejection is provided. The method may include applying a machine learning model to identify artefactual independent components in transcranial magnetic stimulation electroencephalogram data collected during a transcranial magnetic stimulation procedure. Clean transcranial magnetic stimulation electroencephalogram data is generated by removing, from the transcranial magnetic stimulation electroencephalogram data, the artefactual independent components. Real-time adjustments to parameters of the transcranial magnetic stimulation procedure may be performed based on the clean transcranial magnetic stimulation electroencephalogram data. Related systems and articles of manufacture, including computer program products, are also provided.

Abstract: A method may include applying, to a corpus of data, a first machine learning technique to identify candidate domains of an ontology mapping brain structure to mental function. The corpus of data may include textual data describing a plurality of mental functions and spatial data corresponding to a plurality of brain structures. A second machine technique may be applied to optimize a quantity of domains included in the ontology and/or a quantity of mental function terms included in each domain. The ontology may be applied to phenotype an electronic medical record and predict a clinical outcome for a patient associated with the electronic medical record. Related systems and articles of manufacture, including computer program products, are also provided.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

Abstract: Provided herein are, for example, systems and methods of diagnosing and treating depression, in which a transcranial magnetic stimulation (TMS) therapy is administered to a subject in need thereof and measuring a TMS evoked response in the subject, are provided. The systems and methods allow tailoring or optimizing of a treatment protocol for maximal individual benefit, thereby providing an individualized and optimized treatment protocol for psychiatric disorders such as depression.

Abstract: The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic ?7 receptor agonist, a ?3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

Abstract: The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic ?4-?2 and/or ?7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).

Abstract: Provided herein are, for example, systems and methods of diagnosing and treating depression, in which a transcranial magnetic stimulation (TMS) therapy is administered to a subject in need thereof and measuring a TMS evoked response in the subject, are provided. The systems and methods allow tailoring or optimizing of a treatment protocol for maximal individual benefit, thereby providing an individualized and optimized treatment protocol for psychiatric disorders such as depression.

Abstract: Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

Abstract: Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

Abstract: A method may include applying, to a corpus of data, a first machine learning technique to identify candidate domains of an ontology mapping brain structure to mental function. The corpus of data may include textual data describing a plurality of mental functions and spatial data corresponding to a plurality of brain structures. A second machine technique may be applied to optimize a quantity of domains included in the ontology and/or a quantity of mental function terms included in each domain. The ontology may be applied to phenotype an electronic medical record and predict a clinical outcome for a patient associated with the electronic medical record. Related systems and articles of manufacture, including computer program products, are also provided.

Abstract: A method for machine learning based artifact rejection is provided. The method may include applying a machine learning model to identify artefactual independent components in transcranial magnetic stimulation electroencephalogram data collected during a transcranial magnetic stimulation procedure. Clean transcranial magnetic stimulation electroencephalogram data is generated by removing, from the transcranial magnetic stimulation electroencephalogram data, the artefactual independent components. Real-time adjustments to parameters of the transcranial magnetic stimulation procedure may be performed based on the clean transcranial magnetic stimulation electroencephalogram data. Related systems and articles of manufacture, including computer program products, are also provided.

Abstract: Provided herein are, for example, systems and methods of diagnosing and treating depression, in which a transcranial magnetic stimulation (TMS) therapy is administered to a subject in need thereof and measuring a TMS evoked response in the subject, are provided. The systems and methods allow tailoring or optimizing of a treatment protocol for maximal individual benefit, thereby providing an individualized and optimized treatment protocol for psychiatric disorders such as depression.

Abstract: The disclosures provided herewith relate to diagnosis and treatment of post-traumatic stres disorder (PTSD).

Abstract: The disclosures provided herewith relate to systems and methods for mapping personalized brain circuits (or brain network) and/or any abnormalities therein for an individual subject and remediating a treatment protocol based on the personalized map.

Abstract: Brain stimulation methods and devices in which at least two separate magnetic pulse sources with interposed space between them are placed over two distinct brain regions. The coils are pulsed at between 1 and 100 milliseconds apart (e.g., between 5 ms and 40 ms), thereby producing neuroplastic effects upon a third brain region that is network-connected to said first and second regions.

Abstract: Systems and methods for diagnosing and treating psychiatric disorders are provided. For example, in one embodiment, the systems and methods generally include: (a) presenting an emotional conflict task to a patient; (b) receiving an input from the patient in response to the emotional conflict task; (c) assessing the patient's response to the emotional conflict task; and (d) modifying the emotional conflict task based on the patient's response. Such systems and methods may also be employed in a computerized training system for treating a patient with, or at risk of, a psychiatric disorder by training the patient's implicit emotional regulation.